Abstract

CANAKINUMAB OUTCOMES IN COMBINATION WITH CHEMOTHERAPY IN NSCLC PATIENTS

*Hari Chandana Punukula, Puligari Praveen Reddy and Kallem Sharat Venkat Reddy

ABSTRACT

Inflammation is best known for its natural and adaptive contributions to immunity. But there is new insight into the dynamic and essential role of inflammation in the development and growth of tumors, namely chronic inflammation can facilitate tumorigenesis, invasiveness and even metastasis and affects the host immunity subversion. Chronic inflammation has involved a multitude of proteins and cytokines, in particular the interleukin-1β known to be a vital pro inflammatory cytokine, which can cause an inflammatory mediator cascade, encouraging angiogenesis, invasivity of the tumor, and metastasis. In a large-scale analysis of the impact of inflammatory regulation of the antibody in heart disease, interleukin-1β inhibitory with the antibody canakinumab was recently emphasised. The incidence of lung cancer (67% relative reduction of risk) decreases substantially in the high-risk population. This review will summarise the role of inflammations in the spread of cancer, address the biological justifications of interleukin-1β for lung cancer, recommend further analysis of canakinumab as a potential attractive mechanism for future lung cancer treatments in antiinflammatory antibodies and discuss future ongoingtrials and emergency treatments.

Keywords: Anti-inflammatory, canakinumab, Canakinumab Anti-Inflammatory Thrombosis Outcomes Study trial, chronic inflammation, Interleukin-1, interleukin-1? inhibitor, Immunotherapy, Non-small cell lung cancer.